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Abstract
Background: Infectious disease epidemics are a constant threat, and while we can strengthen preparedness in
advance, inevitably, we will sometimes be caught unaware by novel outbreaks. To address the challenge of rapidly
identifying clinical research priorities in those circumstances, we developed and piloted a protocol for carrying out
a systematic, rapid research needs appraisal (RRNA) of existing evidence within 5 days in response to outbreaks
globally, with the aim to inform clinical research prioritization.
Methods: The protocol was derived from rapid review methodologies and optimized through effective use of pre-
defined templates and global time zones. It was piloted using a Lassa fever (LF) outbreak scenario. Databases were
searched from 1969 to July 2017. Systematic reviewers based in Canada, the UK, and the Philippines screened and
extracted data using a systematic review software. The pilot was evaluated through internal analysis and by
comparing the research priorities identified from the data, with those identified by an external LF expert panel.
Results: The RRNA pilot was completed within 5 days. To accommodate the high number of articles identified, data
extraction was prioritized by study design and year, and the clinical research prioritization done post-day 5. Of 118
potentially eligible articles, 52 met the data extraction criteria, of which 46 were extracted within the 5-day time
frame. The RRNA team identified 19 clinical research priorities; the expert panel independently identified 21, of
which 11 priorities overlapped. Each method identified a unique set of priorities, showing that combining both
methods for clinical research prioritization is more robust than using either method alone.
Conclusions: This pilot study shows that it is feasible to carry out a systematic RRNA within 5 days in response to
a (re-) emerging outbreak to identify gaps in existing evidence, as long as sufficient resources are identified, and
reviewers are experienced and trained in advance. Use of an online systematic review software and global time
zones effectively optimized resources. Another 3 to 5 days are recommended for review of the extracted data and
to formulate clinical research priorities. The RRNA can be used for a “Disease X” scenario and should optimally be
combined with an expert panel to ensure breadth and depth of coverage of clinical research priorities.
Keywords: Emerging infectious diseases, Clinical research priorities, Outbreak response, Lassa fever, Rapid research
needs appraisal methodology
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Background
The need and ability to conduct clinical research dur-
ing infectious disease outbreaks to inform current and
future responses is gaining acceptance as a core pillar
of outbreak response [1]. However, the unpredictable
nature of outbreaks makes outbreak research challen-
ging [2, 3]. Since time is of the essence, researchers,
policy makers, and funders need to rapidly identify key
gaps in evidence at the earliest stages of an outbreak,
so that they can prioritize research to address those
gaps and ensure that any research that is undertaken
has maximal value [4]. Traditional approaches to evi-
dence assimilation, such as systematic reviews, require
time and resources that are unlikely to be available
during an outbreak, with traditional systematic reviews
generally taking at least 12 months [5]. Rapid reviews
are a variation of a systematic review that balances
time constraints with considerations in bias [6], de-
signed to inform healthcare policies and guidelines [7].
Even rapid reviews and scoping reviews might require
1 to 6 months or longer to complete [5, 6, 8, 9]. Fur-
thermore, there is no gold standard approach for rapid
or scoping reviews, with methods varying greatly [5–
11]. This highlights a need for a robust methodology to
rapidly and systematically identify key gaps in know-
ledge and evidence to inform research prioritization
early in outbreaks. To address this, we developed and
piloted a transparent and replicable protocol for carry-
ing out a rapid research needs appraisal (RRNA),
within 5 days in response to (re-) emerging outbreaks
globally. The aim is not to identify and fully appraise
all the available evidence, since this is not feasible
within 5 days. Rather, the aim is to identify important
gaps in evidence and knowledge in a robust, system-
atic, and replicable manner to rapidly inform clinical
research prioritization.
The RRNA was piloted in 2017 using a fictitious
Lassa fever (LF) outbreak scenario. LF is an acute, viral
illness first recognized in Nigeria in 1969 [12]. The
causative pathogen, Lassa virus (LASV), is a zoonotic,
single-stranded RNA arenavirus that is endemic in
Guinea, Liberia, Sierra Leone, and Nigeria, with sea-
sonal peaks in incidence. A limited number of cases
have also been reported from Benin, Burkina Faso, Côte
d’ Ivoire, Ghana, and Togo [13]. LASV has been priori-
tized by the World Health Organization (WHO) as a
high threat pathogen for which there is a need for ac-
celerated research and development [14]. In the begin-
ning of 2018, Nigeria experienced a large outbreak of
LF, with 1999 suspected cases reported by the Nigeria
Centre for Disease Control. Of 437 confirmed cases,
109 died, giving a case fatality rate (CFR) of 25% in
confirmed cases [15]. This article presents the develop-
ment of the RRNA methodology, its piloting and
evaluation using LF as an example, and the research
priorities that were identified.
Methods
The RRNA protocol was developed as a collaboration be-
tween Cochrane Response, the Ottawa Hospital Research
Institute, Evidence Aid, and the UK Public Health Rapid
Support Team staff at the University of Oxford. The
methodology was derived from existing rapid review
methodologies and optimized through the use of global
teams of systematic reviewers across different time zones,
pre-defined screening and data extraction templates and
the use of an online systematic review software (Distil-
lerSR, Evidence Partners, Ottawa, Canada). The protocol
was focused on identifying existing evidence gaps across
pre-defined clinical domains (Additional file 1). These
were defined by researchers and clinicians with previous
experience of clinical research outbreak response. The
RRNA protocol is registered on the Open Science Frame-
work [16], and an online training package has been devel-
oped [17]. The 5-day process is illustrated in Fig. 1.
Protocol development
A working group of experts with experience in systematic
and rapid review methodologies, information manage-
ment, and clinical infectious disease research was con-
vened. The protocol was developed over 4months
through three face-to-face meetings with members of the
working group and e-mail iterations [16]. The method-
ology was designed to be used for (re-) emerging infec-
tious diseases where existing evidence and knowledge is
expected to be limited and for the purposes of this exer-
cise was focused on clinical aspects, rather than epidemio-
logical, animal, or ecological studies. Therefore, the
protocol was designed to be inclusive with a focus on
identifying all relevant articles presenting the outcomes of
clinical research, including conference abstracts and on-
going clinical trials. The protocol was piloted in a
two-stage process. Prior to piloting, experienced system-
atic reviewers based across three different time zones
(Canada, the UK, the Philippines) were engaged and
trained in the methodology and the use of the DistillerSR
online systematic review software. The systematic re-
viewers programmed the generic RRNA screening and
data extraction forms into DistillerSR prior to piloting. A
Dropbox folder was set up for sharing of documents. An
online instant messenger group was also set up to allow
queries to be posted and answered rapidly by all members
of the team.
The processes, including the evidence search strategy,
the handover of information, and the data extraction tem-
plate were initially piloted over 1 day using a fictitious
Nipah virus outbreak scenario. This process mini-pilot
was evaluated through feedback from all involved in the
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pilot at a conference meeting call. The feedback informed
updates to the data extraction table and the handover pro-
cesses. The final RRNA protocol was subsequently piloted
fully over 5 days using a fictitious LF outbreak scenario.
Lassa fever pilot
Outside of this pilot study, the process would be triggered
when a decision is taken that there is a need to carry out a
RRNA in response to a (re-) emerging outbreak. Depend-
ing on the setup, this decision may be taken by a steering
group, which can be separate or the same as the coordinat-
ing team (CT). For this pilot, the steering group based at
the University of Oxford, consisting of clinical researchers
with experience in infectious disease outbreak response
and systematic reviews also acted as the CT. The pilot was
triggered by the CT on 17 July 2017. At the start of the
pilot, the CT reviewed and updated the search databases
and inclusion criteria considering the nature of the out-
break scenario. The updated protocol, specific to the LF
outbreak scenario, was then submitted via e-mail to the in-
formation specialist based in Glasgow, UK, and the system-
atic review teams based in London, UK; Ottawa, Canada;
and Manila, the Philippines, together with the fictitious
outbreak report and supporting clinical information about
LF from the US Centers for Disease Control and Preven-
tion (CDC).
Figure 2 illustrates the tasks carried out by the system-
atic review teams involved in the Lassa fever pilot.
The review team based at Cochrane Response in the UK
updated the protocol in DistillerSR accordingly, while the
information specialist carried out the search. The search
was completed on day 1, and the result submitted as an
Endnote library to the systematic review team in London
for uploading into DistillerSR.
Search strategy
An information specialist searched the following elec-
tronic databases for articles published from 1969 until 17
July 2017: MEDLINE (PubMed), EMBASE (OVID), the
Cochrane Library (including the Cochrane Database of
Systematic Reviews and Cochrane Central Register of
Controlled Trials), DARE (Database of Abstracts of Re-
views of Effect), Epistemonikos, and PROSPERO. More-
over, the following trial registries: Clinicaltrials.gov, the
Fig. 1 The 5-day rapid research needs appraisal process
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WHO International Clinical Trials Registry Platform
(ICTRP), the ISRCTN registry, and the websites of WHO,
CDC, and the European Centre for Disease Prevention
and Control (ECDC), using the search terms described in
Box 1. There were no language restrictions applied.
Eligibility
One systematic reviewer screened titles and abstracts for
inclusion using DistillerSR, with a second reviewer screen-
ing all papers deemed ineligible by the first reviewer. Any
disagreements were passed to the next level of screening.
Full-text articles were screened independently by two re-
viewers and consensus on disagreements reached by in-
volving a third reviewer. Articles not found through the
automated or manual search were excluded due to
non-accessibility given the time constraints. These were
listed with full bibliography in the final report. All articles
presenting human, clinical LF quantitative research were
included. Qualitative studies, non-human animal and cell
studies, were excluded. Studies only presenting data on
community transmission from zoonotic sources were ex-
cluded, since the objective was on clinical research. There
were no language limitations at the screening stages.
Data extraction
The data extraction was limited to core data essential for
identifying gaps across the pre-defined clinical research
domains (Additional file 1). The pre-defined data extrac-
tion table was designed to facilitate extraction of (1) bibli-
ography, (2) study design, (3) study objectives, (4) number
of participants, (5) populations covered, (6) interventions
and/or exposure, (7) comparators, and (8) outcomes [16].
Risk of bias assessment or grading of evidence beyond the
above data extraction was not done.
The protocol specified that one systematic reviewer per-
formed the data extraction from the included papers. A
second researcher would then do a random check of 10%
of all qualitative data and 100% of the quantitative data ex-
tracted. For prioritization purposes, articles would be ex-
tracted in order of study design and publication date, with
study designs providing a higher level of evidence and
most recently published articles prioritized. Data would
not be extracted from studies whose design provided a
lower level of evidence, such as case series and case re-
ports, when data were available from studies providing a
higher level of evidence for the clinical domains addressed
in the article. The final data extraction table was submitted
to the CT as an Excel file by mid-day on day 5, together
with the list of bibliographies of the articles not extracted,
with reasons provided and a PRISMA flow chart.
Gaps analysis and clinical research prioritization
The final data extraction table was reviewed by one mem-
ber of the CT, who organized and summarized the level of
evidence and outcomes identified for each clinical domain
and incorporated the findings into a final report post-day
5 of the RRNA process. The final report was submitted to
the CT. The members of the CT subsequently identified
gaps in evidence by reviewing the extracted data for each
clinical domain, by study design, study objectives, popula-
tions covered, interventions/exposure, and outcomes pre-
sented and through a round of iterations and consensus
discussions over 2 days defined key clinical research prior-
ities, informed by the gaps in evidence identified.
Pilot evaluation
The full RRNA pilot was evaluated in a two-step process.
Firstly, a brief survey was sent to everyone involved in the
pilot, asking about facilitators and barriers experienced.
The survey responses were collated by the CT and
discussed during a telephone conference a week after
completion of the pilot. Secondly, an expert panel of three
LF experts was asked to independently identify seminal ar-
ticles and LF clinical research priorities. The panel mem-
bers independently identified clinical research priorities
and seminal articles from their previous experience of
Lassa fever research. These were submitted to the team at
Oxford University via e-mail, de-duplicated and consoli-
dated into one list. The list of seminal articles was com-
pared with the articles included in the RRNA, and articles
excluded due to non-accessibility. The clinical research
priorities were compared with those identified by the CT
from the RRNA data.
Box 1 Search terms
Embase, PubMed:
We used search terms for “Lassa fever” in text words and
controlled vocabulary, in conjunction with terms to define the
different questions (domains): incubation, symptom*, “natural
history”, “clinical features”, transmission, infectiousness, vaccin*,
prophyla*, chemoprophyla*, prevention, protection, diagnosis,
diagnostic, RDT*, screening, detection, immunity, serology,
treatment, management, therapy, drug*,
intervention*,“supportive care”, fluid*, electrolyte*, supplement*,
mortality, death, “adverse events”, “side effect*”, complications,
sequela*. For all other sources we only used search terms for
Lassa fever or Lassa virus.
Cochrane Library, DARE, Epistomonikos, Prospero, Clinical trial
registries (clinicaltrials.gov, ISRCTN registry), WHO), CDC and
ECDC:
“Lassa fever” or “Lassa virus”
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Results
Process
The CT reviewed and updated the protocol as appropriate
for the LF outbreak scenario and submitted it to the infor-
mation specialist and all systematic review teams on day
1. The information specialist completed the search and
submitted the results as an Endnote library to the system-
atic review teams on day 1 (Table 1).
Screening of title and abstracts began before the end of
day 1, started by the review team in Canada, followed by
Fig. 2 The rapid research needs appraisal pilot global “relay” teams
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the Philippines, then the UK, optimizing use of global
time zone, and was completed by day two, with 39% (n =
428/1104) of records passing this step and requiring fur-
ther assessment. In parallel to the screening of title and
abstracts, the information specialist retrieved full-text pa-
pers using Endnote’s automatic retrieval function. This
was complemented by a manual search of papers not re-
trieved automatically. The full-text papers were submitted
to the review teams and uploaded to DistillerSR in sec-
tions. Using the software allowed review processes to be
carried out in parallel, while reducing the need for hand-
overs. As soon as papers were deemed potentially eligible,
another reviewer could start the full-text screening
followed by data extraction, while others continued
screening of title and abstracts (Table 1). In tandem, elec-
tronic copies of journal articles could be uploaded in the
system, and progress tracked in real time. Issues were
dealt with via the online instant messenger group and dur-
ing a brief daily mid-day Skype meeting between the re-
view teams. Two members of the CT were on standby to
assist throughout the 5 days.
The full-text screening started on day 2, but the final
conflicts were not resolved until early on day 5 (acceptance
rate 28% (n = 118/428). Of the included articles, the study
design was identified for 93% (n = 110/118) within the time
frame. After study design prioritization, 47% (n = 52/110) of
the included articles with study design identified, qualified
for data extraction. Most of these (88% (n = 46/52)) were
extracted by mid-day on day 5.
The search was completed earlier than planned, which
meant that the screening of title and abstracts and
full-text papers commenced earlier than scheduled.
However, the retrieval and screening of full-text papers
and resolution of conflicts took longer than anticipated.
This was partly due to the higher than expected number
of articles identified for a (re-) emerging infectious dis-
ease and because Endnote’s automatic paper retrieval
only retrieved 51% (n = 565/1104) of the articles as PDFs
(n = 436) or URL links (n = 129). The remaining full-text
papers, which passed through the first title and abstract
screening step (n = 249), were searched for manually by
members of the CT through the University of Oxford
online library access. Papers not found after the manual
search (n = 145) were excluded due to inaccessibility, in-
stead listed with full bibliography in the final report
(Additional file 2). Most of these articles were not ac-
cessible due to being published in non-English languages
and journals. There were no systematic reviews or ran-
domized controlled trials (RCTs) identified amongst the
non-accessible articles. The data extraction table was
submitted to the CT as a Microsoft Excel file by mid-day
on day 5. This was supplemented by a PRISMA flow
chart and bibliographies of the studies which were ex-
cluded due to not being accessible within the time frame
(Additional file 2) or included but not being data ex-
tracted (Additional file 3). The unexpected retrieval and
resolution of full-text article delays meant that the pro-
portional check of the extracted data by a second re-
viewer was not completed within the 5 days. Instead, a
member of the CT checked 30% of the extracted data
post-day 5.
Outcomes and gaps in evidence
The data extracted were comprehensive, as would be re-
quired for a systematic review. However, for the purpose
of the RRNA, in order to enable identification of gaps in
evidence and knowledge in a short timeframe, the data
were streamlined by a member of the CT to highlight the
key PICO (Population, Intervention, Comparison, Out-
come) parameters required for this purpose, in addition to
Table 1 The RRNA pilot progress from day 1 to 5
Team Day 1 Day 2 Day 3 Day 4 Day 5
Coordinating
team (CT)
❖ Pilot triggered
❖ Protocol reviewed, updated,
and submitted to information
specialist and SRT
❖ Manual retrieval of
full-text articles
❖ Full-text articles
uploaded to Dropbox
as pdfs
❖ Manual retrieval
of full-text articles
❖ Full-text articles
uploaded to Dropbox
as pdfs
❖ Data collated
and incorporated
into the final
report at the end
of day 5
Information
specialist
❖ Search completed
❖ Search result submitted
to the SRT as Endnote file
❖ Automatic full-text
article retrieval (Endnote)
❖ Full-text articles
submitted as pdf’s
or URLs
Systematic review
teams (SRT)
❖ Title and abstract screening ❖ Title and abstract
screening
❖ Full-text screening
❖ Full-text screening
❖ Data extraction
❖ Full-text screening
❖ Data extraction
❖ Full-text screening
❖ Final resolution
of conflicts
❖ Data extraction
❖ Data extraction
table and associated
information submitted
to the CT via e-mail
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bibliography, study design, and setting. Data queries were
resolved via e-mail after completion of the pilot. Due to
the high number of articles identified and the amount and
complexity of data extracted, tidying and organizing of the
data to facilitate identification of gaps in evidence took
longer than expected. The final report was submitted to
the steering group, together with a PRISMA flowchart and
the supplements 3 days post-pilot completion. Gaps in evi-
dence were identified, individually by members of the CT,
through a review of the extracted data for each clinical do-
main. A narrative summary of the level of evidence and
gaps in evidence identified from the data by clinical do-
mains is provided below.
Characteristics of the included studies
The electronic literature search identified 1104 records,
published between 1969 and July 2017, of which 118 met
the inclusion criteria (Fig. 3). Study design and clinical do-
mains addressed in the articles were identified for 110 of
the articles. There were no systematic reviews, meta-ana-
lysis, or RCTs identified. Two were non-randomized con-
trolled studies, 34 cohort studies (some of which included
before and after comparisons), 4 case-control studies, 12
cross-sectional studies, 27 case series, and 31 case reports
(Table 2).
The articles were prioritized so that data were extracted
first from studies whose design provided the highest level of
evidence. Ongoing studies and conference abstracts were
also prioritized, since they can present important prelimin-
ary findings. Case series and case reports were not extracted
when higher level of evidence was available for all the clin-
ical domains addressed in the article. Of the 110 articles, 52
met the data extraction criteria and 46 were extracted within
the 5 days [18–27, 32–34, 36–48, 97–104, 107, 109–112,
114, 119, 121–124, 127]. Twenty-seven case series and 31
case reports were not extracted due to higher level of evi-
dence being available for the domains addressed in the arti-
cles. Six cohort studies [28–31, 108, 120] and eight articles
[128–135] without study design identified were not ex-
tracted due to resource limitations (Additional file 3). Of the
46 data extracted articles (Additional file 4), most were
set-in low-income countries in West Africa: Sierra
Leone (n = 19), Nigeria (n = 17), Liberia (n = 5), Guinea
(n = 2), and Mali (n = 2). Five were indicated as set-in
high-income countries: the USA (n = 3), Germany (n = 2),
and the UK (n = 1). Three articles presented studies set in
more than one country [48, 114, 121]. Five were confer-
ence abstracts [33–36, 41] and two ongoing cohort studies
registered by the US Army, evaluating effectiveness and
safety of ribavirin, expected to be completed in 2018 and
2019 [121, 122]. Table 3 presents an overview of the study
setting, populations, objectives, and interventions identi-
fied for the studies in each clinical domain.
Clinical phenotype and natural history of disease
Seventy-seven articles identified addressed this domain
(Table 2). After prioritization by study design, 29 articles
published from 1975 to 2017 qualified for data extraction,
of which 25 were extracted within the time frame. These
articles reported data on almost 7000 people, representing
more than 1700 confirmed LF cases (Table 3). Most of the
studies were set in West Africa. Fourteen studies were set
in Nigeria [18, 19, 21, 22, 24, 26, 33, 34, 36, 39, 41, 42, 48,
127], seven in Sierra Leone [20, 25, 27, 40, 43, 45, 48],
three in Liberia [23, 46, 48], three in Mali [32, 47, 48], and
one in the USA [48]. One study was set in multiple loca-
tions [48]. The five conference abstracts identified related
to studies in this domain. Four cohort studies published
from 1974 to 2001 [28–31] were not extracted due to re-
source limitations (Additional file 3).
Symptoms of LF on presentation and during hospital
admission in healthcare settings in West Africa were de-
scribed in 15 studies [19, 21, 23–27, 33, 35, 36, 39–41, 45,
48]. The data shows that LF has been studied in adult and
pediatric populations in lower income healthcare settings
in West Africa. Most of the studies were observational
studies, and many lacked data on case definition, diagnos-
tic criteria used to support the findings, or risk factors,
such as comorbidities or immunosuppression through
age, illness, or medication. Another gap identified was the
quantification of the risk of complications, more severe
disease, and sequelae in different at-risk populations.
Eleven studies presented data on CFR with standard care:
six were set in Nigeria [22, 26, 33–35, 39], three in Sierra
Leone [25, 27, 43], and two in Liberia [23, 46]. The CFR
ranged from 5.6 to 75%, but with limited information to
explain the wide variations observed in different settings
or description of the standard care provided.
Transmission and prevention
Twenty-three articles were identified for this domain; 13
qualified for data extraction and data were extracted for
12 of these, reporting data from 1980 participants, includ-
ing nearly 300 confirmed cases of LF (Tables 2 and 3).
The studies were set in Sierra Leone (n = 5) [38, 43, 98,
100, 103], Nigeria (n = 4) [22, 42, 101, 102], Liberia (n = 1)
[104], Germany (n = 1) [99], the UK (n = 1) [97], and the
USA [103]. One study was set in more than one country
[103]. Several of the studies reported risk of nosocomial
transmission to other patients and healthcare workers [22,
38, 42, 43, 104], with attack rates ranging from 11 to 55%
in different settings [22, 104]. Four studies reported the
use of ribavirin as post-exposure prophylaxis (PEP) [98,
100–102], administered to a different level of contacts. A
total of 64 Lassa fever contacts were treated with the drug.
Though it was evident that there is a risk of transmission
from body fluids in hospital settings, there were no robust
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studies identified studying risk of transmission from differ-
ent types of body fluids or organs, moreover, a lack of
standardization of definitions of a “contact.”
Diagnostic
Fourteen studies were available for this domain; eight
qualified for data extraction, and seven were extracted
Fig. 3 PRISMA flowchart
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within the time frame (Table 2). Four of the extracted stud-
ies were set in Sierra Leone [37, 107, 109, 111], two in
Liberia [46, 112], and one in Nigeria [110], providing data
from more than 800 confirmed cases (Table 3). Most iden-
tified studies were observational, with one case-control
study. The studies used different diagnostic tests, with
polymerase chain reaction (PCR) the most commonly
used. Neither a gold standard diagnostic test nor clin-
ical or laboratory case definitions were reported.
Moreover, systematic diagnostic and sampling strat-
egies were not reported. The studies indicated that no
single diagnostic test could detect all cases or strains
of LF [109, 111, 112].
Immune response
Twenty-one studies were identified for this domain;
six articles qualified for data extraction of those five
were extracted within the time frame (Table 2). Two
studies were set in Sierra Leone [107, 114], two in
Guinea [44, 114], one in Mali [32], and one in Liberia
[46]. One study was set in more than one country
[114]. Though there were a limited number of studies
identified, they provided data from more than 4500
participants, including 1400 LF-positive people
(Table 3). One study reported seroprevalence data
from a rural region of Guinea [44], and a cohort
study reported that LF IgM antibodies may persist for
months to years [107]. The data shows that there are
large gaps in evidence regarding the immune response
to LF infection caused by different strains, in different
at-risk populations and over time.
Drug therapy and supportive care
Of 36 articles identified for this domain, 11 qualified for
data extraction and ten were extracted within the time
frame (Table 2). Four studies were set in Sierra Leone
[38, 119, 123, 124], four in Nigeria [19, 21, 24, 42], and
two ongoing studies by the US Army [121, 122] (set in
the USA and Germany), providing data for more than
1500 participants and almost 800 LF cases (Table 3).
The highest level of evidence in this domain was a
non-randomized controlled study set in Sierra Leone
(1986, n = 312), which studied the effect of ribavirin and
convalescent plasma therapy. It was a relatively small
study, which showed no reduction in case fatality rates
using LF convalescent plasma, but indicated that ribavi-
rin was effective, especially if administered within the
first 6 days of illness [119].
Risk factors for more severe disease
There were four studies identified and data extracted for
this domain (Table 2). The studies were set in Sierra
Leone [37, 38, 107, 114] and Guinea [44, 114]. One
study was set in both countries [114]. The data repre-
sented more than 2000 participants and over 500 con-
firmed or probable LF cases (Table 3). A number of
studies reported that elevated aspartate aminotransferase
levels were associated with increased mortality rates [37,
38, 107], one study also reported a correlation between
low levels of blood urea nitrogen, alkaline phosphatase,
and alanine aminotransferase and survival [107]. Two
studies reported an association between low levels of a
number of cytokines and survival rates [107, 114].
Table 2 Type of study designs identified for each clinical domain
Domain Study design
Non-randomized
controlled studies
Cohort studies Case-control
studies
Cross-sectional
studies
Case series# Case report#
Clinical phenotype
and natural history
of disease
1 article
[18]
18 articles*
[19–38]
3 articles
[39–41]
7 articles
[42–48]
21 articles
[49–69]
27 articles
[70–96]
Transmission and
prevention
10 articles**
[22, 29, 38, 97–103]
3 articles
[42, 43, 104]
3 articles
[61, 62, 105]
7 articles [73, 74,
83, 84, 91, 92, 106]
Diagnostics 5 articles**
[19, 37, 107–109]
1 article [110] 2 articles
[46, 111, 112]
1 article [69] 4 articles [55, 74,
82, 113]
Immune response 4 articles**
[31, 32, 107, 114]
2 articles
[44, 46]
6 articles
[52, 65, 115–118]
9 articles [55, 70, 72,
73, 76, 86, 91–93]
Drug therapy and
supportive care
1 article [119] 7 articles** [19, 21,
24, 38, 120–122]
3 articles
[42, 123, 124]
8 articles [49, 51–53,
56, 64, 66, 125]
17 articles [55, 71,
73–78, 80, 81,
83, 85, 86, 89,
95, 96, 126]
Risk factors for more
severe disease
3 articles [37, 38, 114] 1 article [44]
*4 not extracted
**1 not data extracted
#Not extracted since higher level of evidence available for the domains covered in each article
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Pilot evaluation
Stakeholder pilot evaluation
Some of the key facilitators and barriers identified by the
stakeholders taking part in the pilot, through a short
post-LF pilot survey and subsequent telephone confer-
ence, are presented in Table 4. The evaluation highlighted
that previous training in the methodology and experience
of systematic review methods were key facilitators. More-
over, that use of the online systematic review software and
global time zones was an effective way of optimizing re-
sources. The barriers identified also highlights the need to
ensure that everyone is familiar with all the systems used,
and in identifying sufficient resources at the outset of the
outbreak, tailored to the type of outbreak and number of
articles identified after the initial search.
Clinical research priorities
A comparison of the clinical research priorities identified
by the steering group from the RRNA data with the prior-
ities independently identified by the LF expert panel
shows that though there is overlap, each method identified
unique priorities. Despite the number of articles identified
by the RRNA, the types of studies that were reported
meant that there was limited robust evidence in the clin-
ical domains investigated with inadequacies in the quality
of the reporting (such as a lack of case definitions and
Table 3 Overview of the included studies
Domain No. of extracted
studies
Setting* No. of participants Populations Study objectives Intervention
Clinical phenotype
and natural history
of disease
25 14 Nigeria
7 Sierra
Leone
3 Liberia
3 Mali
1 USA
Total: n = 6680
LF pos. n = 1734
Adults
Pregnant women
Children, Infants,
Neonates
(0 to > 65 years old)
Clinical presentation,
symptoms (n = 15)
LF fatality rate (n = 11)
Biochemical laboratory
parameters (n = 7)
N/A
Transmission and
prevention
12 5 Sierra
Leone
4 Nigeria
1 Germany
1 Liberia
1 UK
1 USA
Total: n = 1980
LF pos: n = 281
Adults
Pregnant women
Children, Infants,
Neonates
(0 to 73 years)
Ribavirin as PEP (n = 4)
Risk of nosocomial
transmission (n = 5)
Ribavirin
Diagnostics 7 4 Sierra
Leone
2 Liberia
1 Nigeria
Total: n = 3338
LF pos: n = 897
Adults
Children
PCR for diagnostics (n = 3)
PCR and hybridization (n = 1)
LFI, ELISA and PCR (n = 1)
IgM as early marker (n = 1)
PCR, LFI, ELISA,
virus isolation
Immune response 5 2 Guinea
2 Sierra
Leone
1 Liberia
1 Mali
Total: n = 4570
LF pos: n = 1437
Adults
Children, Infants
(7 months to
83 years)
Levels of inflammatory
cytokines chemokines and
other pro-inflammatory
mediators (n = 1)
Prevalence of LASV-specific
IgG antibodies (LV IgG) (n = 1)
Population LF seroconversion
(n = 1)
Drug therapy and
supportive care
10 4 Nigeria
4 Sierra
Leone
2 USA
1 Germany
Total: n = 1516
LF pos: n = 792
Adults
Pregnant women
Children, Infants,
Neonates
(0 to 65 years)
Therapeutic effectiveness of
Ribavirin (n = 9)
Therapeutic effectiveness of LF
convalescent plasma therapy
(n = 2)
Ribavirin treatment adverse
event (n = 1)
Ribavirin iv.
Ribavirin oral
Convalescent
plasma
Risk factors for more
severe disease
4 3 Sierra
Leone
2 Guinea
Total: n = 2110
LF pos. or probable:
n = 562
Adults
Pregnant women
Children, Infants,
Neonates
(0 to > 60 years)
Correlation of cytokine levels
and outcome (n = 2)
Correlation of AST and
outcomes (n = 1)
Correlation of BUN, ALP, ALT,
and outcomes (n = 1)
Correlation of viremia level
and outcome (n = 1)
Risk factors for positive LASV
IgG (n = 1)
Abbreviations: LF Lassa fever, LASV Lassa virus, Pos positive, PEP post-exposure prophylaxis, PCR polymerase chain reaction, LFI lateral flow immunoassay, ELISA
enzyme-linked immunosorbent assay, Ig immunoglobulin, AST aspartate aminotransferase, BUN blood urea nitrogen, ALP alkaline phosphatase, ALT
alanine aminotransferase
*Some studies were set in more than one country
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methods used for diagnostics). This meant that the steer-
ing group, through a review of the extracted data, identi-
fied several clinical research priorities where important
uncertainties and evidence gaps remain. These are pre-
sented in the table, together with the clinical research pri-
orities identified by the independent LF expert panel
(Table 5). Of the 19 clinical research priorities informed
by the RRNA data, 11 of those were also listed as priorities
by the expert panel, together with an additional ten re-
search priorities. This shows that the RRNA methodology
was able to identify most of the priorities identified by the
Lassa fever expert panel, together with an additional eight
unique priorities not identified by the expert panel. The
priorities identified by the expert panel tended to be more
specific, whereas the priorities identified from the RRNA
covered a wider focus.
Seminal articles
There were 21 seminal articles identified by the LF ex-
pert panel. These were all identified by the RRNA search
strategy, although 13 did not meet the inclusion criteria
for the RRNA and were excluded at the screening stage,
mainly due to being animal or cell culture studies. The
remaining eight articles [25, 44, 60, 62, 63, 65, 96, 119]
were all included in the RRNA. Three of these articles
[25, 44, 119] met the data extraction criteria and were
extracted. The other five [60, 62, 63, 65, 96] were case
series or case reports and not extracted, instead included
with full bibliography. This shows that the RRNA suc-
cessfully identified and included all seminal articles iden-
tified by the LF expert panel which met the RRNA
inclusion eligibility criteria.
Discussion
The development and piloting of the RRNA process
demonstrates that a global partnership, through
effective use of time zones, can deliver a robust sum-
mary of much of the published clinical research evi-
dence on Lassa fever within 5 days in response to an
outbreak. The results show that the RRNA method-
ology can be a valuable tool for rapidly identifying
gaps in evidence and informing clinical research pri-
orities in response to (re-) emerging outbreaks glo-
bally, ideally combined with an expert panel for
further refinement of the research priorities.
Key strengths of the process were the use of experienced
systematic reviewers, trained in the RRNA methodology
in advance and based across different global time zones
for resource optimization. Use of an online systematic re-
view software allowed various steps in the review process
to be carried out in parallel, minimizing handovers and
knowledge transfer loss. The RRNA protocol was devel-
oped specifically for emerging outbreaks where previous
clinical research is likely limited. Therefore, the protocol
was designed to be over-inclusive at the screening stage,
with the aim to reduce the risk of any relevant studies be-
ing missed. However, for the LF pilot, the number of arti-
cles retrieved and deemed eligible was higher than
expected from previous experiences for a re-emerging
outbreak, which meant that the full-text screening and
data extraction took longer than anticipated. This was al-
leviated by the prioritization of the data extraction step,
whereby lower levels of evidence were not extracted if a
higher level of evidence were identified for the clinical do-
mains covered. Furthermore, articles in languages other
than English were included but not data extracted. For the
future, we recommend that resources should be allocated
in relation to the number of articles identified at the
search stage. Moreover, depending on the nature of the
outbreak and region of endemicity of the pathogen, re-
viewers with appropriate language skills can be identified
at the outset.
Table 4 Protocol facilitators and barriers identified
Facilitators Barriers
• Review teams with previous experience of systematic and rapid reviews
involving clinical research was a key facilitator for protocol development
and piloting
• An experienced information specialist for developing and carrying out a
rapid, robust search strategy
• Engaging stakeholders involved in the pilot in the development of the
protocol ensured all were trained in the methodology in advance
• The brief clinical LF background data summarized by the CT were
submitted to all on day 1
• The “global relay” set up in advance, which optimized the use of time
zones and resources
• The use of DistillerSR allowed the organization of the data and different
steps to be carried out in parallel. It also reduced the need for handovers,
though the reviewers found that a brief, daily handover meeting was useful
• The use of an instant messenger system aided the rapid response to
specific queries
• The CT on stand-by as extra resources was helpful in order to respond to
clinical queries and assisting with full-text paper retrieval and consensus
• Endnotes’ automatic retrieval of full-text articles was not as effective
as expected. This meant that additional resources had to be
identified rapidly to assist with retrieving full-text papers, causing
unforeseen delays
• The higher than expected number of articles identified meant that
resources were stretched to capacity
• Screening of full-text papers took longer than expected
• The reviewers found some of the clinical domains, such as
diagnostics and immune response harder to review and
data extract
• The large number of articles identified also meant that there were
not enough resources to translate non-English papers
• One review team not having access to Endnote during the pilot
• The large amount of data extracted meant that it took longer than
anticipated to tidy and organize the data
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Table 5 Lassa fever clinical research priorities identified
Clinical phenotype and natural history of disease RRNA Expert panel
Which are the populations at risk? ✓ ✓
What is the true incidence of asymptomatic infection; is the reported 85% of asymptomatic infections true or is there a
diversity of clinical presentation?
✓
What are the clinical characteristics of Lassa fever in different at-risk populations? ✓
What are the long-term health sequelae and what is their frequency, severity, and duration? ✓ ✓
What are the underlying pathophysiological mechanisms of death and are these preventable e.g. acute kidney injuries?
What is the cause of platelet dysfunction in acutely ill Lassa patients?
✓ ✓
What is the clinical and epidemiology relevance of Lassa virus sequence heterogeneity? ✓
Transmission and prevention
What are the risks of person-to-person transmission associated with different types of exposure e.g. to what extent and
how does human-human transmissions account for disease transmission? What is the risk of transmission from different
body fluids and organs?
✓ ✓
Does disease severity vary with route of transmission? ✓
Does genetic differences within and between Lassa virus strains results in differences in transmission and in disease
phenotype?
✓
Who are the target population for a Lassa vaccine, e.g. does asymptomatic infection protect against re-infection? Does
presence of antibodies protect from re-infection?
✓ ✓
Does ribavirin PEP reduce the risk of Lassa virus disease, or more severe disease? ✓
What is the optimal route and dosing for post-exposure prophylaxis with ribavirin (e.g. oral vs. intravenous)? ✓ ✓
How diverse does a vaccine need to be to protect against all strains of Lassa virus? ✓
Diagnostics
Can we develop a diagnostic test that is highly sensitive and specific for all lineages? ✓ ✓
How does sequence variation/heterogeneity impact diagnostic methods and accuracy? ✓
What is the optimal sampling time frame for diagnostics using RT-PCR? How many days after symptoms does Lassa
virus become detectable by PCR?
✓
Can we develop a validated point-of-care test for use in different healthcare settings, including rural health posts? ✓ ✓
Immune response
What are the dynamics of resistance to re-infection? What is the average kinetics of antibody responses following acute
Lassa fever virus infection and what is the variability between individuals and by age?
✓ ✓
In what sites and for how long does virus persist? What are the risk factors for virus persistence? ✓
Does previous exposure to Lassa virus result in more severe disease upon subsequent re-exposure (e.g. vaccine) as a result
of antibody-dependent enhancement of infection, i.e. could a vaccine do harm?
✓
What immunological end-points should be used for Lassa virus vaccine trials? ✓
Drug therapy and supportive care
What is the true efficacy and safety of ribavirin for the treatment of Lassa? Can we transition acutely ill Lassa patients to
oral ribavirin once viral loads are decreasing?
✓ ✓
Does the use of ribavirin in acute Lassa fever virus infection improve clinical outcomes compared to supportive care alone? ✓ ✓
What is the optimal approach to supportive care for acutely ill patients with Lassa and other VHFs? ✓
What is the target therapeutic plasma and CSF concentrations of ribavirin for the treatment of Lassa fever virus infection?
Do current oral and IV treatment regimens achieve these target concentrations?
✓
Can type 1 interferon therapy boost the efficacy of ribavirin? Is there a role for therapies directed at host immunopathology
in the management of Lassa fever?
✓
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In this pilot, the reviewers found that the diagnos-
tics and immune response domains were more diffi-
cult to process, in regard to assessing which articles
to include and relevant data to extract. This delayed
the reaching of consensus at the full-text screening
stage and the data extraction. Engaging reviewers with
relevant content expertise as well as those with ex-
pertise in systematic review screening and data ex-
traction processes, and ensuring understanding of all
domains in advance, could help with the speedier
resolution of queries and identification of the key
data to extract.
Despite the high number of articles identified, the
RRNA was able to identify key clinical research articles,
which enabled the CT to identify a broad range of gaps in
evidence and clinical research priorities across all do-
mains, including eight unique research questions not
identified by the expert panel. Prospective clinical obser-
vational studies of patients with Lassa fever could answer
many of the key evidence gaps, such as risk factors and
pathophysiological mechanisms for severe disease, infect-
ivity of body tissues, long-term sequelae, and immuno-
logical responses. A need for diagnostic studies was also
identified by both the RRNA method and the experts and
could be nested within clinical observational studies. In
addition, clinical trials are needed to evaluate the use of
supportive care strategies, ribavirin, and other potential
therapeutics. Given the fairly predictable timing and loca-
tion of LF cases, all these research questions should be
tractable given sufficient resources and effort.
Although there was an overlap of research questions
identified by the RRNA team and the panel members,
both methods identified unique research questions. The
questions identified by the RRNA team tended to be
broader, whereas the expert panel identified more focused
questions. This shows that using both methods can lead
to a more robust and comprehensive set of research prior-
ities that covers all domains, while ensuring specificity,
than relying on either process alone. All seminal papers
that fit the inclusion criteria were identified by the RRNA
methodology. The number of seminal papers highlighted
by the panel that did not fit the inclusion criteria empha-
sizes the need to ensure that all stakeholders are fully
trained in the process in advance, ideally through a brief-
ing meeting to ensure full understanding of the process.
The pilot evaluation shows that it is feasible to carry out
a robust RRNA within 5 days in response to an outbreak,
to inform clinical research priorities. Another 3 to 5 days
are recommended for summarizing and reviewing the ex-
tracted data, in order to identify gaps in evidence and to
formulate clinical research priorities. The resource limita-
tions encountered can be minimized by identifying re-
viewers, depending on the number of articles identified at
the search stage. Depending on the nature of the outbreak,
e.g., endemicity, reviewers with specific language skills
should be engaged. Identifying experts for the panel took
longer than anticipated and although the clinical re-
searchers who formed the expert panel for this pilot had
years of experience in LF research, in collaboration with
research groups in endemic areas, engaging experts from
endemic areas would be desirable. For sustainability, it is
important to identify a pool of clinical researchers and sys-
tematic reviewers globally, with a focus on infectious dis-
ease “hot spot” regions, that are trained in the process and
on “stand-by” ready to be activated. Moreover, it is im-
portant to engage a pool of global emerging infectious dis-
ease experts in advance. The fact that the time
commitment is limited minimizes the time spent away
from other work commitments and can act as an import-
ant facilitator. Timely and effective data sharing during a
public health emergency and potential copyright issues
around sharing of non-open access articles are other chal-
lenges that need to be addressed in advance.
Conclusions
This pilot study shows that the RRNA methodology can
be used to systematically and transparently identify im-
portant research gaps, in days and weeks rather than
months or years. The findings highlight that using a
RRNA together with input from a disease-specific expert
panel can ensure that a wider range of clinical research
priorities is identified than if using either method on its
own. The pilot illustrates the benefit of global research
networks, but also a need to strengthen networks in epi-
demic “hot spot” regions, which could ensure people with
appropriate language skills and contextual expertise are
trained and engaged in future RRNAs. The RRNA is not
intended to replace systematic reviews, or to generate data
for a meta-analysis, but as a tool to inform rapid research
prioritization when there are no systematic reviews or
Table 5 Lassa fever clinical research priorities identified (Continued)
Clinical phenotype and natural history of disease RRNA Expert panel
Risk factors for more severe disease
Are reported differences in CFR attributable to differences in case mix (e.g. illness severity on presentation to a healthcare
facility), differences in the underlying prevalence of risk factors for death, or differences in the care provided?
✓
Are there clinical features or biomarkers of the risk of progression to severe disease that have clinical utility? ✓
Do genetic differences within and between Lassa strains results in differences in disease phenotype and disease severity? ✓
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robust RCTs available, such as for many of the WHO pri-
ority pathogens [14]. As well as expanding to other dis-
eases areas, it is also important that the gaps that a RRNA
identifies for a particular disease are re-visited periodically
and in the context of the outbreak. For instance, for Lassa
fever, this might include the need for additional research
on circulating strains, rate of infectivity, risk groups, risk
of transmission from body fluids, re-infection, and health
outcomes. These results show that the RRNA can fill in
gaps not identified by the expert panel, and the expert
panel can help refine the research priorities further. The
RRNA methodology can be used in response to any (re-)
emerging outbreak globally, when there is no recent sys-
tematic review available and applied for the scenario of a
“disease X” [14] epidemic.
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